| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| Coxiella burnetii | Injection | 50 microgram/mL | Resolved | Available | Manufacturing | 31/01/2025 |
| Coxiella burnetii | Injection | 5 microgram/mL | Resolved | Available | Manufacturing | 31/01/2025 |
| carvedilol | Tablet, film coated | 6.25 mg | Anticipated | Available | Manufacturing | 31/01/2025 |
| olanzapine pamoate monohydrate | Injection, powder for | 931 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 31/01/2025 |
| olanzapine pamoate monohydrate | Injection, powder for | 690 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 31/01/2025 |
| olanzapine pamoate monohydrate | Injection, powder for | 483 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 31/01/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 1200000 USP Unit | Resolved | Available | Manufacturing | 31/01/2025 |
| fentanyl | Drug delivery system, transdermal | 8.4 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 31/01/2025 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Current | Unavailable | Manufacturing | 31/01/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 31/01/2025 |
| azithromycin dihydrate | Tablet, film coated | 524.05 mg | Current | Unavailable | Manufacturing | 31/01/2025 |
| trandolapril | Capsule, hard | .5 mg | Current | Limited Availability | Manufacturing | 31/01/2025 |
| quetiapine fumarate | Tablet, modified release | 172.695 mg | Anticipated | Available | Unexpected increase in consumer demand | 31/01/2025 |
| quetiapine fumarate | Tablet, modified release | 57.565 mg | Anticipated | Available | Unexpected increase in consumer demand | 31/01/2025 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Current | Unavailable | Manufacturing | 31/01/2025 |
| metoprolol succinate | Tablet, modified release | 95 mg | Current | Limited Availability | Manufacturing | 31/01/2025 |
| raloxifene hydrochloride | Tablet, film coated | 60 mg | Current | Unavailable | Unexpected increase in consumer demand | 31/01/2025 |
| docetaxel | Injection, concentrated | 80 mg | Resolved | Available | Manufacturing | 31/01/2025 |
| candesartan cilexetil | Tablet, uncoated | 4 mg | Current | Limited Availability | Manufacturing | 31/01/2025 |
| escitalopram oxalate | Tablet, film coated | 12.74 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 31/01/2025 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Current | Unavailable | Manufacturing | 31/01/2025 |
| buprenorphine | Drug delivery system, transdermal | 5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 31/01/2025 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Resolved | Available | Manufacturing | 31/01/2025 |
| tenofovir disoproxil maleate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Current | Limited Availability | Manufacturing | 31/01/2025 |
| irbesartan~hydrochlorothiazide | Tablet, film coated | 300 mg~12.5 mg | Current | Limited Availability | Manufacturing | 31/01/2025 |
| hydrochlorothiazide~irbesartan | Tablet, film coated | 25 mg~300 mg | Current | Unavailable | Manufacturing | 31/01/2025 |
| tadalafil | Tablet, film coated | 20 mg | Current | Unavailable | Manufacturing | 31/01/2025 |
| ivabradine hydrochloride | Tablet, film coated | 5.39 mg | Current | Limited Availability | Manufacturing | 31/01/2025 |
| cisplatin | Injection, concentrated | 1 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 31/01/2025 |
| pregabalin | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 31/01/2025 |
| olanzapine | Tablet, uncoated | 2.5 mg | Resolved | Available | Manufacturing | 31/01/2025 |
| levothyroxine sodium | Tablet, uncoated | .05 mg | Anticipated | Available | Unexpected increase in consumer demand | 31/01/2025 |
| gentamicin sulfate | Injection, solution | 135.6 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 31/01/2025 |
| tamoxifen citrate | Tablet, uncoated | 15.2 mg | Current | Limited Availability | Manufacturing | 31/01/2025 |
| levodopa~carbidopa monohydrate | Tablet, uncoated | 100 mg~26.9 mg | Current | Limited Availability | Manufacturing | 31/01/2025 |
| cabergoline | Tablet, uncoated | 1 mg | Resolved | Available | Manufacturing | 31/01/2025 |
| midazolam | Injection, solution | 5 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 31/01/2025 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Resolved | Available | Manufacturing | 31/01/2025 |
| reboxetine mesilate | Tablet, uncoated | 5.224 mg | Current | Limited Availability | Manufacturing | 31/01/2025 |
| prazosin hydrochloride | Tablet, uncoated | 2.19 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 30/01/2025 |
| fludarabine phosphate | Injection, concentrated | 50 mg | Resolved | Available | Manufacturing | 30/01/2025 |
| sodium fluoride | Injection, concentrated | 1 mg/mL | Current | Unavailable | Manufacturing | 30/01/2025 |
| olmesartan medoxomil~hydrochlorothiazide~amlodipine besilate | Tablet | 40 mg~25 mg~6.944 mg | Current | Limited Availability | Manufacturing | 30/01/2025 |
| eftrenonacog alfa | Injection, powder for | 250 IU | Current | Unavailable | Unexpected increase in consumer demand | 30/01/2025 |
| cyclopentolate hydrochloride | Eye Drops, solution | 10 mg/mL | Resolved | Available | Manufacturing | 30/01/2025 |
| ropivacaine hydrochloride monohydrate | Injection, solution | 2.116 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 30/01/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Anticipated | Available | Manufacturing | 30/01/2025 |
| cisplatin | Injection, concentrated | 1 mg/mL | Current | Limited Availability | Manufacturing | 30/01/2025 |
| encorafenib | Capsule, hard | 75 mg | Resolved | Available | Manufacturing | 30/01/2025 |
| estradiol | Drug delivery system, transdermal | .39 mg | Current | Limited Availability | Manufacturing | 30/01/2025 |
| estradiol hemihydrate | Tablet, film coated | 2.06 mg | Anticipated | Available | Manufacturing | 30/01/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Resolved | Available | Unexpected increase in consumer demand | 30/01/2025 |
| testosterone enantate | Injection | 250 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 29/01/2025 |
| clozapine | Oral Liquid, suspension | 50 mg/mL | Current | Unavailable | Manufacturing | 29/01/2025 |
| pentetic acid | Injection, powder for | 5 mg | Current | Emergency Supply Only | Manufacturing | 29/01/2025 |
| medronic acid | Injection, powder for | 10 mg | Current | Unavailable | Manufacturing | 29/01/2025 |
| rizatriptan benzoate | Wafer | 14.53 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 29/01/2025 |
| epirubicin hydrochloride | Injection, concentrated | 200 mg | Current | Unavailable | Manufacturing | 29/01/2025 |
| Follitropin alfa | Injection, solution | 150 IU | Anticipated | Available | Manufacturing | 29/01/2025 |
| benzatropine mesilate | Injection | 1 mg/mL | Resolved | Available | Manufacturing | 29/01/2025 |
| clonazepam | Tablet, uncoated | .5 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 29/01/2025 |
| buprenorphine | Patch, dermal | 30 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 29/01/2025 |
| oxaliplatin | Injection, concentrated | 100 mg | Current | Limited Availability | Manufacturing | 29/01/2025 |
| fluticasone propionate | Inhalation, pressurised | 125 microgram/actuation | Resolved | Available | Unexpected increase in consumer demand | 29/01/2025 |
| tobramycin | Injection, solution | 80 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| salbutamol sulfate | Inhalation, conventional | 3 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| sodium pyrophosphate | Injection, powder for | 30 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| trihexyphenidyl (benzhexol) hydrochloride | Tablet, uncoated | 5 mg | Current | Limited Availability | Unexpected increase in consumer demand | 28/01/2025 |
| omega3acid ethyl esters 90 | Capsule, soft | 1000 mg | Anticipated | Available | Manufacturing | 28/01/2025 |
| oxytocin | Injection, solution | 10 IU | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 28/01/2025 |
| doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Resolved | Available | Manufacturing | 28/01/2025 |
| clonidine hydrochloride | Tablet, uncoated | 100 microgram | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 28/01/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Anticipated | Available | Manufacturing | 28/01/2025 |
| quetiapine fumarate | Tablet, modified release | 460.52 mg | Current | Limited Availability | Manufacturing | 28/01/2025 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Resolved | Available | Manufacturing | 28/01/2025 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 28/01/2025 |
| duloxetine hydrochloride | Capsule, enteric | 33.66 mg | Current | Unavailable | Unexpected increase in consumer demand | 28/01/2025 |
| duloxetine hydrochloride | Capsule, enteric | 67.32 mg | Resolved | Available | Commercial Changes / Commercial viability | 28/01/2025 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 182 microgram/mL | Current | Unavailable | Manufacturing | 28/01/2025 |
| tranexamic acid | Injection, solution | 100 mg/mL | Resolved | Available | Manufacturing | 28/01/2025 |
| cisatracurium besilate | Injection, solution | 14.07 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 28/01/2025 |
| amiodarone hydrochloride | Injection, solution | 150 mg | Anticipated | Available | Manufacturing | 28/01/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 28/01/2025 |
| mupirocin | Ointment | 20 mg/g | Current | Limited Availability | Unexpected increase in consumer demand | 28/01/2025 |
| fluorouracil | Injection, solution | 50 mg/mL | Current | Unavailable | Manufacturing | 28/01/2025 |
| risperidone | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| risperidone | Tablet, film coated | 3 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 28/01/2025 |
| risperidone | Tablet, film coated | 4 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| pregabalin | Capsule, hard | 75 mg | Current | Unavailable | Unexpected increase in consumer demand | 28/01/2025 |
| dimethyl fumarate | Capsule, enteric | 120 mg | Current | Limited Availability | Manufacturing | 28/01/2025 |
| tamoxifen citrate | Tablet | 30.34 mg | Current | Limited Availability | Manufacturing | 28/01/2025 |
| levothyroxine sodium | Tablet | .05 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| levothyroxine sodium | Tablet | .2 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| levothyroxine sodium | Tablet | .1 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| levothyroxine sodium | Tablet | .075 mg | Current | Unavailable | Manufacturing | 28/01/2025 |
| olanzapine | Tablet, uncoated | 5 mg | Anticipated | Available | Manufacturing | 28/01/2025 |
2025年2月3日